Breaking News Instant updates and real-time market news.

BIIB

Biogen

$294.07

-8.7 (-2.87%)

, FWP

Forward Pharma

$22.13

0.18 (0.82%)

12:47
12/01/16
12/01
12:47
12/01/16
12:47

Biogen's Tecfidera patent feud may pose risk, WSJ says

Biogen (BIIB) faced oral arguments this week in a patent interference hearing brought by a small Danish biotech company, Forward Pharma (FWP), regarding "its best-selling multiple sclerosis drug, Tecfidera," says the Wall Street Journal. With analysts expecting Biogen to book almost $4B in Tecfidera sales this year, representing more than a third of total sales for the drug giant, a win by Forward Pharma would impact Biogen, added the WSJ. Also according to the report, sales of Biogen's other best selling drugs Avonex and Tysabri are slowing. Reference Link

BIIB

Biogen

$294.07

-8.7 (-2.87%)

FWP

Forward Pharma

$22.13

0.18 (0.82%)

  • 07

    Dec

BIIB Biogen
$294.07

-8.7 (-2.87%)

11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Overweight
Piper's Schimmer proclaims amyloid hypothesis is not dead
Piper Jaffray analyst Joshua Schimmer says the failure of Eli Lilly's (LLY) solanezumab is not the final nail in the amyloid hypothesis coffin. Biogen (BIIB) and Eisai's aducanimab study is the most potent approach for amyloid lowering, Schimmer tells investors in a research note. He points out that he was skeptical whether solanezumab's effect was adequate. "Our view of Alzheimer's for amyloid is informed not so much by the extremely sloppy science in that disease, but by consistent cause/effect signals across other amyloidosis," Schimmer writes. He believes today's selloff in shares of Biogen "creates some breathing room." The analyst recommends looking to build a position in Biogen after the stock settles down. Schimmer reiterates an Overweight rating on the shares with a $335 price target. The stock is down 8%, or $24.41, to $293.70 in pre-market trading.
11/23/16
MSCO
11/23/16
NO CHANGE
MSCO
Overweight
Morgan Stanley expects big reversal today in Biogen shares
Morgan Stanley Matthew Harrison expects shares of Biogen (BIIB) to end the trading day flat or slightly higher. The stock is currently down $26.61, or 8%, to $291.50 in pre-market trading. With Biogen's aducanumab more potent than Eli Lilly's solanezumab, the Alzheimer's drug still has potential for success, Harrison tells investors in a research note. He points out that Lilly management noted that "the study results, including many secondary clinical endpoints, directionally favored solanezumab." Harrison sees hope in the amyloid hypothesis. The analyst has an Overweight rating on Biogen.
11/23/16
SBSH
11/23/16
NO CHANGE
Target $305
SBSH
Buy
Citi sees four reasons why Biogen Alzheimer's drug can still work
Citi analyst Robyn Karnauska sees four reasons why Biogen's (BIIB) Alzheimer's drug aducanumab can still work following the failure of Eli Lilly's (LLY) solanezumab. The analyst lists difference in mechanism of action, efficacy in an end-point-dependent manner, patient population and endpoints as why she thinks Biogen's drug can have a different outcome than Lilly's. The analyst has a Neutral rating on Biogen with a $305 price target.
11/23/16
JEFF
11/23/16
NO CHANGE
Target $310
JEFF
Buy
Biogen selloff may be an overreaction, says Jefferies
Jefferies analyst Brian Abrahams believes selloff in shares of Biogen (BIIB) following Eli Lilly's (LLY) Alzheimer's failure may be an overreaction. Signals of activity seen for Lilly's sola "do maintain some possibility" that Biogen's aducanumab could "ultimately make it over the line," Abrahams tells investors in a research note. He keeps a Hold rating on Biogen with a $310 price target, however, viewing the risk/reward as balanced.
FWP Forward Pharma
$22.13

0.18 (0.82%)

03/11/16
LEER
03/11/16
NO CHANGE
LEER
Outperform
Europe revoked Biogen's Tecfidera dosing patent, says Leerink
Leerink analyst Jason Gerberry points out that the European Patent Office yesterday revoked Biogen's (BIIB) Tecfidera dosing patent. The '537 patent in Europe is equivalent to the U.S. '514 patent subject to an ongoing patent interference versus Forward Pharma (FWP), Gerberry tells investors in a research note. The European Patent Office's detailed opinion explaining the rationale for the revocation has not yet published and may not be available for about a month, the analyst points out. He believes Europe's decision has "zero read-through" to the U.S. patent dispute between Forward and Biogen. Gerberry has an Outperform rating on Forward Pharma.
03/14/16
JMPS
03/14/16
NO CHANGE
JMPS
Forward Pharma has positive read through from patent ruling, says JMP Securities
After Biogen's (BIIB) '537 EU patent was revoked, JMP Securities thinks the news is positive for Forward Pharma (FWP). According to the firm, Forward now has the only patent in Europe for a 480 mg Dimethyl fumarate drug for the treatment of MS. The firm keeps a $33 price target and Outperform rating on Forward.
04/11/16
SBSH
04/11/16
NO CHANGE
Target $345
SBSH
Buy
Citi calls potential Biogen hemophilia sale 'surprising and confusing'
Citi analyst Robyn Karnauskas admits being "surprised and confused" after Reuters reported Friday that Biogen (BIIB) is exploring a sale of its hemophilia business. The analyst estimates the business is worth $4.8B-$6.4B. Biogen could use the cash to acquire a bigger strategic asset and/or buybacks, or may be trying to make itself "lean and more attractive as a potential M&A target," Karnauskas tells investors in a research note. She believes, however, that a takeout of Biogen "may be hard" given the uncertainty related to the Forward Pharma (FWP) patent issue regarding Tecfidera. Since the hemophilia business is growing at a time when peers in the sector are looking to diversify, investors will likely be confused should the unit be sold, Karnauskas writes. She keeps a Buy rating on Biogen.
08/03/16
JMPS
08/03/16
NO CHANGE
JMPS
Forward has positive read through from Biogen speculation, says JMP Securities
JMP Securities analyst Jason Butler thinks that acquisition speculation regarding Biogen (BIIB) highlights "underappreciated value" in Forward Pharma's IP portfolio. He continues to believe that Forward is undervalued, and he keeps a $33 price target and Outperform rating on the shares.

TODAY'S FREE FLY STORIES

PCRX

Pacira

$35.70

-0.6 (-1.65%)

20:00
09/19/17
09/19
20:00
09/19/17
20:00
Recommendations
Pacira analyst commentary  »

Pacira's Exparel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

AVEVF

Aveva

19:56
09/19/17
09/19
19:56
09/19/17
19:56
Upgrade
Aveva rating change  »

Aveva upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZLAB

Zai Lab

18:58
09/19/17
09/19
18:58
09/19/17
18:58
Syndicate
Zai Lab announces upsizing of U.S. IPO of American depositary shares »

Zai Lab announces its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

OHI

Omega Healthcare

$32.53

-0.12 (-0.37%)

18:30
09/19/17
09/19
18:30
09/19/17
18:30
Hot Stocks
Omega Healthcare provides hurricane update »

Omega Healthcare provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

F

Ford

$11.72

0.09 (0.77%)

18:30
09/19/17
09/19
18:30
09/19/17
18:30
Periodicals
Ford to slash production at five North American assembly plants, Reuters says »

Ford announced it intends…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 03

    Oct

  • 26

    Oct

FDX

FedEx

$216.00

0.92 (0.43%)

18:26
09/19/17
09/19
18:26
09/19/17
18:26
Hot Stocks
FedEx says without cyberattack FY18 guidance would not have changed »

Comments are from the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 21

    Sep

  • 25

    Sep

EE

El Paso Electric

$54.85

0.05 (0.09%)

18:25
09/19/17
09/19
18:25
09/19/17
18:25
Hot Stocks
El Paso Electric announces City of El Paso approved settlement terms »

El Paso Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

18:17
09/19/17
09/19
18:17
09/19/17
18:17
Hot Stocks
Bed Bath & Beyond says biggest component in drop of FY17 EPS view is operations »

Company dropped its FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

CPRT

Copart

$32.54

-0.32 (-0.97%)

18:11
09/19/17
09/19
18:11
09/19/17
18:11
Earnings
Copart reports Q4 EPS 30c, consensus 29c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

STLD

Steel Dynamics

$33.83

0.03 (0.09%)

18:04
09/19/17
09/19
18:04
09/19/17
18:04
Earnings
Steel Dynamics sees Q3 adjusted EPS 63c-67c, consensus 70c »

Steel Dynamics provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XBKS

Xenith Bankshares

$29.96

0.42 (1.42%)

17:58
09/19/17
09/19
17:58
09/19/17
17:58
Hot Stocks
Treasury exits stake in Xenith Bankshares »

Xenith Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$62.93

0.23 (0.37%)

17:54
09/19/17
09/19
17:54
09/19/17
17:54
Periodicals
Breaking Periodicals news story on Bristol-Myers »

Times:NHS will supply…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 18

    Oct

  • 26

    Oct

  • 09

    Nov

  • 05

    Mar

BBBY

Bed Bath & Beyond

17:54
09/19/17
09/19
17:54
09/19/17
17:54
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

DESP

Despegar.com

17:52
09/19/17
09/19
17:52
09/19/17
17:52
Syndicate
Despegar.com 12.7M share IPO priced at $26.00 »

The IPO priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

WAC

Walter Investment

$0.65

0.186 (40.09%)

17:50
09/19/17
09/19
17:50
09/19/17
17:50
Hot Stocks
Walter Investment says Barclays to increase financing available »

On September 13, Walter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBAY

CymaBay

17:49
09/19/17
09/19
17:49
09/19/17
17:49
Initiation
CymaBay initiated at Cantor »

CymaBay initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

BBBY

Bed Bath & Beyond

17:46
09/19/17
09/19
17:46
09/19/17
17:46
Hot Stocks
Bed Bath & Beyond sees net drop in Bed Bath & Beyond stores in FY17 »

Says rate of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

EVH

Evolent Health

$15.65

-0.8 (-4.86%)

17:45
09/19/17
09/19
17:45
09/19/17
17:45
Initiation
Evolent Health initiated at KeyBanc »

Evolent Health initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

BPL

Buckeye Partners

$56.33

0.64 (1.15%)

17:44
09/19/17
09/19
17:44
09/19/17
17:44
Syndicate
Buckeye Partners announces $210M in limited partnership unit sales »

Buckeye Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RL

Ralph Lauren

$91.03

0.87 (0.96%)

17:43
09/19/17
09/19
17:43
09/19/17
17:43
Initiation
Ralph Lauren initiated at Barclays »

Ralph Lauren initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

PVH

PVH Corp.

$127.47

-0.54 (-0.42%)

17:43
09/19/17
09/19
17:43
09/19/17
17:43
Initiation
PVH Corp. initiated at Barclays »

PVH Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

, ORIG

Ocean Rig UDW

$0.16

-0.0083 (-4.90%)

17:43
09/19/17
09/19
17:43
09/19/17
17:43
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Gemphire…

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

ORIG

Ocean Rig UDW

$0.16

-0.0083 (-4.90%)

IOVA

Iovance Biotherapeutics

$8.55

0.3 (3.64%)

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

FDX

FedEx

$216.00

0.92 (0.43%)

ADBE

Adobe

$156.60

0.83 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 21

    Sep

  • 25

    Sep

  • 25

    Sep

  • 22

    Oct

KORS

Michael Kors

$46.18

1.53 (3.43%)

17:42
09/19/17
09/19
17:42
09/19/17
17:42
Initiation
Michael Kors initiated at Barclays »

Michael Kors initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

L Brands

$39.23

-0.75 (-1.88%)

17:42
09/19/17
09/19
17:42
09/19/17
17:42
Initiation
L Brands initiated at Barclays »

L Brands initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBI

Hanesbrands

$24.71

-0.02 (-0.08%)

17:41
09/19/17
09/19
17:41
09/19/17
17:41
Initiation
Hanesbrands initiated at Barclays »

Hanesbrands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.